Smart chemo: tailoring treatment for HER2+ breast cancer to reduce side effects
NCT ID NCT07239271
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase III trial tests a personalized approach for HER2-positive breast cancer, where treatment is adjusted based on early response (ctDNA and imaging). The goal is to reduce chemotherapy side effects without compromising effectiveness. The study will enroll 2000 women with early or locally advanced breast cancer across China.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- albumin-bound paclitaxel, trastuzumab, pertuzumab, docetaxel, carboplatin, pyrotinib, T-DM1, T-DXd, everolimus
- What this could lead to
- If successful, this could lead to a more personalized treatment approach for HER2-positive breast cancer, reducing chemotherapy side effects while maintaining high cure rates.
- What could go wrong
- This is a large phase III trial but results are not yet available. The adaptive strategy is complex and may not outperform standard therapy. Some drugs tested (like everolimus) have shown only modest benefits in advanced disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PATIENTS WITH HER2-POSITIVE BREAST CANCER (BC) SUITABLE FOR NEOADJUVANT THERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.